Zydus Lifesciences Sirolimus Tablets bags USFDA okay
The drug will be manufactured at the group's formulation manufacturing facility at Moraiya.
Ahmedabad: Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) for Sirolimus Tablets, 1 mg and 2 mg (USRLD: Rapamune Tablets).
Rapamune is used to prevent rejection (anti-rejection medicine) in people 13 years of age and older who have received a kidney transplant. It is also given to treat a rare lung disorder called lymphangioleiomyomatosis which predominantly affects women of childbearing age.
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya.
Sirolimus Tablets had annual sales of USD 69mn in the United States (IQVIA MAT Dec. 2022). The group now has 342 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Zydus Lifesciences bags tentative USFDA nod for Canagliflozin Tablets
Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited), an Indian Pharmaceutical company is a fully integrated, global healthcare provider. The company was founded in the year 1952 by Mr. Ramanbhai B. Patel (late), a first-generation entrepreneur and a doyen in the field of Indian Pharmaceuticals.
Read also: USFDA nod to Zydus Lifesciences hypertension drug
